Víctor Albarrán-Artahona· @vmalbarran · X·· 13 小时前评分70
正文 · 原文
Personalized cancer vaccines are becoming a clinical reality! 🧬
INTerpath-001: intismeran + pembrolizumab improves 2-year RFS in resected melanoma:
82.2% vs 70.0% (HR 0.58).
A major milestone for mRNA immunotherapy. Now awaiting mature OS data.
#ESMO26 @myESMO @OncoAlert
90 浏览 · 1 赞 · 1 转发 · 0 回复
会议摘要
LBA1按 Presidential Symposium I 对上
INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL)
https://esmocongress.esmo.orgINTerpath-001
https://esmocongress.esmo.org来源：Víctor Albarrán-Artahona · x.com